Inhaled liposomal ciprofloxacin in patients with non-cystic fibrosis bronchiectasis and chronic lung infection with Pseudomonas aeruginosa (ORBIT-3 and ORBIT-4): two phase 3, randomised controlled trials
Open Access
- 15 January 2019
- journal article
- research article
- Published by Elsevier BV in The Lancet Respiratory Medicine
- Vol. 7 (3), 213-226
- https://doi.org/10.1016/s2213-2600(18)30427-2
Abstract
No abstract availableKeywords
This publication has 38 references indexed in Scilit:
- Mechanisms of immune dysfunction and bacterial persistence in non-cystic fibrosis bronchiectasisMolecular Immunology, 2013
- Bronchiectasis-Associated Hospitalizations in Germany, 2005–2011: A Population-Based Study of Disease Burden and TrendsPLOS ONE, 2013
- Short- and Long-Term Antibiotic Treatment Reduces Airway and Systemic Inflammation in Non–Cystic Fibrosis BronchiectasisAmerican Journal of Respiratory and Critical Care Medicine, 2012
- Evaluating Success of Therapy for BronchiectasisClinics in Chest Medicine, 2012
- A Randomized Controlled Trial of Nebulized Gentamicin in Non–Cystic Fibrosis BronchiectasisAmerican Journal of Respiratory and Critical Care Medicine, 2011
- British Thoracic Society guideline for non-CFbronchiectasisThorax, 2010
- Addition of Inhaled Tobramycin to Ciprofloxacin for Acute Exacerbations of Pseudomonas aeruginosa Infection in Adult BronchiectasisSocial psychiatry. Sozialpsychiatrie. Psychiatrie sociale, 2006
- Fluoroquinolone Toxicity Profiles: A Review Focusing on Newer AgentsClinical Infectious Diseases, 1999
- Treatment of Idiopathic Bronchiectasis With Aerosolized Recombinant Human DNase ISocial psychiatry. Sozialpsychiatrie. Psychiatrie sociale, 1998
- Cox's Regression Model for Counting Processes: A Large Sample StudyThe Annals of Statistics, 1982